This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01103/identifier/chemspider/
n7http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01103/identifier/chebi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01103/identifier/wikipedia/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01103/identifier/pharmgkb/
n16http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB01103/identifier/pdb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01103/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01103/identifier/pubchem-compound/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01103/identifier/pubchem-substance/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01103/identifier/drugbank/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01103
rdf:type
n3:Drug
n3:description
An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. [PubChem]
n3:generalReferences
# Canete R, Escobedo AA, Gonzalez ME, Almirall P: Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children. World J Gastroenterol. 2006 Oct 21;12(39):6366-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17072963 # Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y: The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol. 2006 Apr;63(4):299-303. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16623930 # Zipper J, Cole LP, Goldsmith A, Wheeler R, Rivera M: Quinacrine hydrochloride pellets: preliminary data on a nonsurgical method of female sterilization. Int J Gynaecol Obstet. 1980;18(4):275-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6109672 # Bhatt RV: Camp laparoscopic sterilization deaths in Gujarat State, India, 1978-1980. Asia Oceania J Obstet Gynaecol. 1991 Dec;17(4):297-301. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1839351 # Peterson HB, Lubell I, DeStefano F, Ory HW: The safety and efficacy of tubal sterilization: an international overview. Int J Gynaecol Obstet. 1983 Apr;21(2):139-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6136433
n3:group
approved
n3:halfLife
5 to 14 days
n3:indication
For the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions.
owl:sameAs
n11:DB01103 n16:DB01103
dcterms:title
Quinacrine
adms:identifier
n13:Quinacrine n14:PA164745551 n17:232 n18:DB01103 n20:8711 n21:237 n22:46507828 n23:C07339 n24:QUM
n3:mechanismOfAction
The exact mechanism of antiparasitic action is unknown; however, quinacrine binds to deoxyribonucleic acid (DNA) in vitro by intercalation between adjacent base pairs, inhibiting transcription and translation to ribonucleic acid (RNA). Quinacrine does not appear to localize to the nucleus of Giaridia trophozoites, suggesting that DNA binding may not be the primary mechanism of its antimicrobial action. Fluorescence studies using Giardia suggest that the outer membranes may be involved. Quinacrine inhibits succinate oxidation and interferes with electron transport. In addition, by binding to nucleoproteins, quinacrine suppress the lupus erythematous cell factor and acts as a strong inhibitor of cholinesterase.
n3:packager
n5:271B3F6F-363D-11E5-9242-09173F13E4C5
n3:synonym
6-chloro-9-((4-(Diethylamino)-1-methylbutyl)amino)-2-methoxyacridine 3-chloro-7-Methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine 2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine N(4)-(6-chloro-2-Methoxy-9-acridinyl)-N(1),N(1)-diethyl-1,4-pentanediamine Mepacrine Quinacrine
n3:toxicity
Oral, rat: LD<sub>50</sub> = 900 mg/kg; Oral, mouse: LD<sub>50</sub> = 1000 mg/kg. Symptoms of overdose include seizures, hypotension, cardiac arrhythmias, and cardiovascular collapse.
n3:proteinBinding
80-90%
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Quinacrine.htm
n6:hasConcept
n7:M0018330
n3:IUPAC-Name
n4:271B3F75-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F7B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F7A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F77-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F78-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F79-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F8A-363D-11E5-9242-09173F13E4C5 n4:271B3F73-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F8C-363D-11E5-9242-09173F13E4C5 n4:271B3F74-363D-11E5-9242-09173F13E4C5 n4:271B3F71-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F72-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B3F8D-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:P01AX05
n3:H-Bond-Acceptor-Count
n4:271B3F81-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F82-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F7C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F7D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F7F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F7E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F80-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed rapidly from the gastrointestinal tract following oral administration.
n3:affectedOrganism
Parasitic protozoa and helminths
n3:casRegistryNumber
83-89-6
n3:category
n3:containedIn
n15:271B3F70-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B3F86-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F88-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F89-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3F8B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F85-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F84-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F87-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F76-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3F83-363D-11E5-9242-09173F13E4C5